Cellevat3d® nanofiber macrocarriers
Cellevat3d® nanofiber macrocarriers
| Material | Nanofiber-based cellulose |
| Format | Cross-linked fibers |
| Bioreactor | Packed- & fixed-bed bioreactors |
| Applications | Cell therapy, MSCs, vaccines, recombinant proteins, organoid formation |
Cellevat3d® nanofiber macrocarriers is in development. Expected launch 2026.
Production of human mesenchymal stem cells (hMSCs) on Cellevat3d® nanofiber macrocarriers
Human mesenchymal stem cells (hMSCs) grown on Cellevat3d® nanofiber macrocarriers showed a 19-fold increase in cell density with retained high cell viability after 8 days of cell culture, indicating superior cell adhesion and growth within the scaffold. Importantly, cell harvesting was successfully achieved using TrypLE enzymatic dissociation.
Stem cell identity and quality of the produced hMSCs was further confirmed by the expected level of key cell surface markers analyzed by flow-cytometry. Also, hMSCs passaged into 2D culture following culture on the nanofiber macrocarriers reestablished monolayer cultures with the same morphology and proliferative capability as prior to culturing on the nanofiber macrocarriers.
The macrocarriers development project will proceed during 2025 with the optimization, integration, evaluation, and validation of scale-up in packed bed bioreactors for the commercial launch in cell therapy applications planned for 2026.
Sign up for product news
Sign up for product news about our upcoming upstream product line Cellevat3d® nanofiber macrocarriers or contact us to book a meeting by filling in the form below.
